Unique ID issued by UMIN | UMIN000001149 |
---|---|
Receipt number | R000001396 |
Scientific Title | Amelioration of glucose homeostasis and visceral adiposity in metabolic syndrome by mild electrical current and thermo therapy |
Date of disclosure of the study information | 2008/06/01 |
Last modified on | 2010/01/14 14:21:53 |
Amelioration of glucose homeostasis and visceral adiposity in metabolic syndrome by mild electrical current and thermo therapy
Metabolic ameliorations in metabolic syndrome by MET
Amelioration of glucose homeostasis and visceral adiposity in metabolic syndrome by mild electrical current and thermo therapy
Metabolic ameliorations in metabolic syndrome by MET
Japan |
metabolic syndrome
Endocrinology and Metabolism |
Others
NO
To explore the effects of MET on glucose homeostasis and visceral adiposity in metabolic syndrome.
Safety,Efficacy
Changes of biomarkers related to metabolic syndrome at 12 weeks and 24 weeks after MET treatment.
General assessment of MET device evaluated by subjects.
Interventional
Cross-over
Randomized
Individual
Open -no one is blinded
No treatment
2
Treatment
Device,equipment |
12 weeks of MET (4 times a week, 60 min each time), and then 12 weeks of withdrawal, 40 subjects.
12 weeks of no treatment, and then 12 weeks of MET (4 times a week, 60 min each time), 40 subjects.
40 | years-old | <= |
65 | years-old | > |
Male
Abdominal obesity, given as waist circumference
greater than 85 cm with meets 2 criteria in 3 shown below,
i)Triglycerides: greater than or equal to 150 mg/dL and/or HDL cholesterol: less than 40 mg/dL
ii)Systolic Blood pressure: greater than or equal to130 mmHg and/or Diastolic blood pressure: greater than or equal to 85 mmHg
iii)Fasting blood glucose: greater than or equal to 110 mg/dL
i) Past history or current medication of myocardial infarction, angina, apoplexy and arteriosclerosis obliterans.
ii)Severe wound, infections, pre- or post-operation.
iii)Severe liver dysfunction (GOT and/or GPT: greater than 100U).
iv)Chronic heart failure, familial dyslipidemia.
v)Severe diabetic complications.
vi)HbA1c : greater than or equal to 6.5%.
vii)Pacemaker carrier.
80
1st name | |
Middle name | |
Last name | Eiichi Araki |
Graduate School of Medical Sciences,
Kumamoto University
Department of Metabolic Medicine
1-1-1 Honjo, Kumamoto, Japan
096-373-5169
1st name | |
Middle name | |
Last name | Tatsuya Kondo |
Graduate School of Medical Sciences,
Department of Metabolic Medicine
1-1-1 Honjo, Kumamoto, Japan
096-373-5169
t-kondo@gpo.kumamoto-u.ac.jp
Department of Metabolic Medicine,
Graduate School of Medical Sciences,
Kumamoto University
Department of Metabolic Medicine,
Graduate School of Medical Sciences,
Kumamoto University
Self funding
Japanese Red Cross Society, Kumamoto Health Care Center.
NO
2008 | Year | 06 | Month | 01 | Day |
Unpublished
Completed
2008 | Year | 03 | Month | 17 | Day |
2008 | Year | 05 | Month | 01 | Day |
2009 | Year | 12 | Month | 01 | Day |
2008 | Year | 05 | Month | 09 | Day |
2010 | Year | 01 | Month | 14 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000001396